Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "MPD, MDS and Other Blood Disorders" returned 15 results:


Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients with Relapsed AL Amyloidosis
Principal Investigator(s): Keren Osman

Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia
Principal Investigator(s): Ronald Hoffman

A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na administered as a 72-hour continuous intravenous infusion every other week in MDS patients with excess blasts relapsing after, or refractory to, or intolerant to Azacitidine or Decitabine
Principal Investigator(s): Lewis R. Silverman

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis – A phase II study
Principal Investigator(s): John O. Mascarenhas

A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease
Principal Investigator(s): Eileen Scigliano

A Phase II Controlled Trial of a Single ProHema-CB unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning For Patients Age 15-55 Years With Hematologic Malignancies
Principal Investigator(s): Luis M. Isola

A phase 1 trial of host dendritic cell infusion after allogenic stem cell transplant for prevention or treatment of relapsed disease in patients with advanced hematologic malignancies
Principal Investigator(s): Keren Osman

Filgrastim-Mobilized Blood Stem Cells for Transplantation
Principal Investigator(s): Luis M. Isola

An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera-Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia-Myelofibrosis (PET-MF)
Principal Investigator(s): John O. Mascarenhas

MPD-RC 111: Single Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High Risk PV or High Risk ET who are Either Hydroxurea Resistent or Intolerant or Have Had Abdominal Vein Thrombosis
Principal Investigator(s): Ronald Hoffman

A Phase 2 trial to evaluate the activity of Imetelstat (GRN136L) in patients with essential thrombocythemia who require Cytoreduction and have failed or are intolerant to previous therapy, or who refuse standard therapy
Principal Investigator(s): Ronald Hoffman

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Principal Investigator(s): Luis M. Isola

A multi-center, open label phase I/II study of CEP-701 (lestaurtinib) in adults with myelofibrosis
Principal Investigator(s): Ronald Hoffman

Phase I/II Study of Combination oral JAK2 tyrosine kinase inhibitor (JAK2-TKI) and Histone Deacetylase Inhibitor (HDACI) therapy in patients with Myelofibrosis
Principal Investigator(s): John O. Mascarenhas

A Phase 2, Multi-Center, Open Label, Randomized, Parallel-Group Study of A Lenalidomide (Revlimid) Regimen or A Sequential Azacitidine (Vidaza) plus Lenalidomide (Revlimid) Regimen versus Conventional Care for Therapy of Subjects 65 Years or Older with Newly Diagnosed Acute Myeloid Leukemia
Principal Investigator(s): Lewis R. Silverman